You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華森製藥(002907.SZ)與中金資本、青島匯融及啟德智融等設立創新生物醫藥股權投資基金
格隆匯 11-24 16:28

格隆匯11月24日丨華森製藥(002907.SZ)公佈,公司於2019年11月22日與中金資本運營有限公司(“中金資本”)、青島匯融啟德股權投資基金(有限合夥)(“青島匯融”)、廈門金圓投資集團有限公司(“金圓集團”)、中金啟融(廈門)股權投資基金合夥企業(有限合夥)(“中金啟融”)、青島西岸匯融啟德股權投資基金(有限合夥)(“西岸匯融”)、廈門市翔安投資集團有限公司(“翔安投資”)、啟德智融(天津)股權投資合夥企業(有限合夥)(“啟德智融”)、河北港口集團有限公司(“河北港口”)、四川欣聞投資有限責任公司(“欣聞投資”)、福建聖農控股集團有限公司(“聖農控股”)、董淑君、深圳滿溢通達科技企業(有限合夥)(“滿溢通達”)和佳德致遠(廈門)股權投資合夥企業(有限合夥)(“佳德致遠”)簽訂了《中金啟德(廈門)創新生物醫藥股權投資基金合夥企業(有限合夥)合夥協議》)及《中金啟德(廈門)創新生物醫藥股權投資基金合夥企業(有限合夥)合夥協議補充協議》,共同投資中金啟德(廈門)創新生物醫藥股權投資基金合夥企業(有限合夥)(“合夥企業”)。

合夥企業募集資金規模為人民幣15億元(具體以實際認繳出資金額為準),其中華森製藥作為有限合夥人認繳出資額為人民幣3000萬元。

合夥企業將主要對生物醫藥行業的各階段的投資項目進行股權投資,並將重點關注創新藥、體外診斷、新型醫療器械、醫療信息化等領域。

根據合夥協議約定合夥企業將主要從事對生物醫藥行業各階段的投資項目進行股權投資,並將重點關注創新藥、體外診斷型醫療器械信息化等領域此次投有利於滿足華森製藥業務拓展和戰略發展的需求,符合華森製藥現有及未來業務發展方向,有利於華森製藥的長遠發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account